Table 2

Characteristics of satellite cell strains obtained from rheumatoid arthritis patients and osteoarthritis patients

Characteristic

RA N = 4

OA N = 8

β

95% CI

P-value


Myogenicity (% desmin positive cells)

After explantation

46 (13)

58 (26)

-0.35

-51 to 19

0.32

After CD56 selection

87 (5)

95 (3)

-0.72

-13 to -2

0.02

After thawing at early replicative phase*

60 (20)

47 (32)

-0.57

-209 to 142

0.62

At mid-term replicative phase#

56 (37)

37 (33)

-0.02

-49 to 46

0.95

At maximum replicative capacity

47 (43)

38 (30)

-0.07

-86 to 77

0.90

After oxidative stress†

21 (12)

16 (10)

0.21

-341 to 349

0.91

Viability (% alive cells)

At early replicative phase*

91 (4)

94 (2)

-0.39

-8 to 4

0.33

After oxidative stress†

33 (24)

34 (24)

0.48

-114 to 153

0.31

Growth characteristics*

Proliferation index‡ (% BrdU positive cells)

86 (2)

85 (6)

-0.05

-10 to 9

0.89

Colony formation (number)

78 (44)

85 (34)

-0.12

-83 to 66

0.78

Myogenic colonies (%)

30 (16)

27 (31)

-0.40

-41 to 7

0.14

Growth speed (PD/day)

0.39 (0.10)

0.32 (0.08)

0.310.28

-0.07 to 0.18-5.0 to 13.9

0.290.28

Maximum replicative capacity (PD)

33.4 (9.7)

27.4 (5.5)

-0.29

-385 to 359

0.73

Proliferation index after oxidative stress†‡

(% BrdU positive cells)

15 (15)

34 (24)

Fusion index at early replicative phase*§

(% of fused myonuclei)

27 (12)

25 (13)

-0.01

-26 to 26

0.99

Normalized protein expression*

p16

103 (15)

140 (63)

-0.62

-85 to 7

0.08

p21

27 (4)

27 (5)

-0.28

-13 to 8

0.60

p53

67 (12)

62 (8)

-0.18

-18 to 11

0.58

hTERT

32 (6)

39 (14)

-0.26

-23 to 11

0.39

Relative telomere length*

(% of ref. cell line 1301)

22 (5)

23 (10)

-0.46

-16 to -0.4

0.04


N, number of subjects; OA, osteoarthritis; RA, rheumatoid arthritis. Beta (β). 95% confidence interval (CI) and P-value are shown for linear regression model adjusted for age and gender, myogenic purity, number of PDs, and batch. Values are given as mean (SD) if not otherwise stated. *Early replicative phase: mean 10.3 (SD 1.7) PDs for myogenic purity, viability, growth characteristics and fusion index; mean 14.4 (SD 3.1) PDs for normalized protein expression and relative telomere length. #Mid-term replicative phase: mean 24.3 (SD 4.2) PDs. †Myogenic purity, viability and proliferation index was measured at early replicative phase, 24 hours after oxidative stress (one hour of 250 μM H2O2 at 37°C) in four OA and in three RA patients. ‡Proliferation index was determined as the percentage of bromodeoxyuridine (BrdU) positive cells after 48 hours of culture with BrdU. §Fusion index was determined as the percentage of fused nuclei (> 2 nuclei per myofiber) in MF20 positive cells.

Duijnisveld et al. Arthritis Research & Therapy 2011 13:R207   doi:10.1186/ar3540

Open Data